When does Apotex's ruxolitinib receive FDA approval?
The pharmaceutical company Apotex has developed a generic version of the medication ruxolitinib, which is used to treat myelofibrosis and polycythemia vera [1]. Myelofibrosis is a type of blood cancer characterized by the replacement of bone marrow with fibrous tissue, while polycythemia vera is a type of blood cancer that causes the body to produce too many red blood cells.
Ruxolitinib, also known as Jakafi, is a Janus kinase (JAK) inhibitor that has been approved by the FDA since 2011 [2]. Apotex's generic version of the medication is expected to receive FDA approval once the original patent expires or is challenged.
When will the exclusivity expire?
The FDA granted a non-extendable New Drug Application (NDA) exclusivity to Incyte Corporation, the current manufacturer of Jakafi, under the Hatch-Waxman Act [3]. Pursuant to the Hatch-Waxman Act, generic manufacturers can file Abbreviated New Drug Applications (ANDA) at least six months prior to the expiration of the original patent.
Since the original patent for Jakafi will expire on September 29, 2028 [4], Apotex's generic version of ruxolitinib may receive FDA approval as early as 2028. However, the actual timing may be affected by various factors, including potential patent disputes, FDA review periods, and litigation.
What happens if Apotex receives FDA approval?
If Apotex receives FDA approval for its generic version of ruxolitinib, patients may benefit from potential price reductions and expanded availability of the medication. Furthermore, increased competition from generic manufacturers can lead to improved quality, innovation, and price containment in the pharmaceutical industry.
Sources:
[1] DrugPatentWatch.com - Ruxolitinib (Jakafi)
[2] incyte.com - Jakafi Product Website (accessed May 2024)
[3] FDA.gov - Hatch-Waxman Act Overview
[4] DrugPatentWatch.com - Ruxolitinib Patent Information